Immunovant Inc (IMVT) Stock Analysis
Verdict: HOLD
Clinical validation in RA and potential best-in-class profile for IMVT-1402 outweigh near-term earnings misses and heavy insider selling.
Investment score: 64/100
Analysis as of
Is Immunovant Inc stock worth reviewing? AI model thesis
The model sees a clinical-stage leader with a validated platform and significant cash runway, currently undergoing a momentum-driven breakout following positive RA data.
7-factor investment score
- Valuation: 45/100 (weight 20%)
- Financial Health: 55/100 (weight 15%)
- Technical Momentum: 85/100 (weight 15%)
- Earnings Quality: 40/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 88/100 (weight 10%)
- Risk-Adjusted Return: 60/100 (weight 15%)
Immunovant Inc opportunities and risks
What speaks for IMVT
- RA Clinical Validation
What speaks against IMVT
- Regulatory/Clinical Failure
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| IMVT | n/a | 0.0x | n/a | 0.0% | 0.0% | -6.0% |
| IBRX | n/a | 57.5x | n/a | 93.8% | -606.2% | -3.7% |
| NUVL | n/a | 0.0x | n/a | 0.0% | 0.0% | -4.2% |
| CELC | n/a | 0.0x | n/a | 0.0% | 0.0% | -2.5% |
| PCVX | n/a | 0.0x | n/a | 0.0% | 0.0% | -11.3% |
| KYMR | n/a | 128.8x | n/a | 100.0% | -612.2% | -3.7% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -3.7% |
Frequently asked questions about Immunovant Inc (IMVT)
Is IMVT stock a good investment?
The cached TradeMates AI model rates Immunovant Inc as HOLD with an investment score of 64/100. The model sees a clinical-stage leader with a validated platform and significant cash runway, currently undergoing a momentum-driven breakout following positive RA data. This is algorithmic model output, not personal investment advice.
Is IMVT stock a buy?
The TradeMates model verdict for IMVT is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.